<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652245</url>
  </required_header>
  <id_info>
    <org_study_id>AZFL-AES-4-001</org_study_id>
    <secondary_id>C1D00571</secondary_id>
    <nct_id>NCT04652245</nct_id>
  </id_info>
  <brief_title>Dymista Allergen Chamber - Onset of Action Study</brief_title>
  <official_title>Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (Dymista) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo in an Environmental Exposure Unit (EEU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the onset of action of fixed drug combination of azelastine&#xD;
      hydrochloride and fluticasone propionate nasal spray (Dymista) in treating the nasal symptoms&#xD;
      of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental&#xD;
      Exposure Unit (EEU).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study will be a single-center, randomized, placebo-controlled, double-blind, and two-period cross-over trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Blinding by overlabelling of Dymista and Placebo bottles.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to onset of action, measured by a difference from placebo in the change from baseline in patient -assessed instantaneous Total nasal symptom score (TNSS) following treatment</measure>
    <time_frame>0 to 4 hours post application</time_frame>
    <description>The sum of the TNSS will contribute to a score ranging from 0 - 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of action, measured by a difference from placebo in the change from baseline in patient-assessed instantaneous total ocular symptom score (TOSS) following treatment</measure>
    <time_frame>0 to 4 hours post application</time_frame>
    <description>The sum of the TOSS will contribute to a score ranging from 0 - 9.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Treatment A (Dymista) and Treatment B (Placebo), separated by at least 14 days of wash-out period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed drug combination of Azelastine hydrochloride 137 μg / Fluticasone propionate 50 μg nasal spray and Placebo nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B (Placebo) and Treatment A (Dymista), separated by at least 14 days of wash-out period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo nasal spray and Fixed drug combination of Azelastine hydrochloride 137 μg / Fluticasone propionate 50 μg nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3</intervention_name>
    <description>Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 3</description>
    <arm_group_label>Treatment A (Dymista) and Treatment B (Placebo), separated by at least 14 days of wash-out period</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5</intervention_name>
    <description>Single dose, one spray in each nostril of Placebo nasal spray at Visit 5</description>
    <arm_group_label>Treatment A (Dymista) and Treatment B (Placebo), separated by at least 14 days of wash-out period</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5</intervention_name>
    <description>Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 5</description>
    <arm_group_label>Treatment B (Placebo) and Treatment A (Dymista), separated by at least 14 days of wash-out period</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3</intervention_name>
    <description>Single dose, one spray in each nostril of Placebo nasal spray, at Visit 3</description>
    <arm_group_label>Treatment B (Placebo) and Treatment A (Dymista), separated by at least 14 days of wash-out period</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent.&#xD;
&#xD;
          2. Male or female subjects (childbearing and non-childbearing potential, non-childbearing&#xD;
             potential defined as females with no menstruation for at least 1 year at screening and&#xD;
             documented FSH &gt; 35 IU/L) aged 18 to 55 years (inclusive) at screening.&#xD;
&#xD;
          3. History of SAR to ragweed pollen for at least the previous 2 ragweed pollen seasons.&#xD;
&#xD;
          4. Positive skin prick test (SPT) response to ragweed pollen (allergen induced wheal&#xD;
             diameter at least 3 mm larger than the negative control). A test performed at Cliantha&#xD;
             Research in the previous 12 months may be used to qualify the subject.&#xD;
&#xD;
          5. Willingness to complete all study visits.&#xD;
&#xD;
             To be eligible for Visit 2 EEU, a subject must additionally comply with the following&#xD;
             criteria:&#xD;
&#xD;
          6. Asymptomatic or with mild symptoms during the baseline recording of symptoms prior to&#xD;
             start of the screening EEU (Visit 2):&#xD;
&#xD;
             • TNSS ≤ 3/12 with the score for each symptom being less than 2.&#xD;
&#xD;
             To be eligible for Visit 3, a subject must additionally comply with the following&#xD;
             criteria during Visit 2 EEU:&#xD;
&#xD;
          7. Demonstrate adequate symptomology:&#xD;
&#xD;
             • TNSS ≥ 6/12 on at least two ePDATTM time point assessments during hours 0-2 in the&#xD;
             EEU (Visit 2), with at least one occurring during the last two time points.&#xD;
             Additionally, subjects will be required to meet a score of at least 2/3 for runny nose&#xD;
             at least twice during hours 0-2 in the EEU, with at least one occurring during the&#xD;
             last two time points.&#xD;
&#xD;
             To be eligible for randomization (Visit 3), a subject must additionally comply with&#xD;
             the following criteria:&#xD;
&#xD;
          8. Demonstrate adequate symptomology:&#xD;
&#xD;
               -  TNSS ≥ 6/12 on at least two ePDATTM time point assessments during hours 0-2 in&#xD;
                  the EEU (Visit 3), with at least one occurring during the last two time points.&#xD;
                  Additionally, subjects will be required to meet a score of at least 2/3 for runny&#xD;
                  nose at least twice during hours 0-2 in the EEU, with at least one occurring&#xD;
                  during the last two time points.&#xD;
&#xD;
               -  No evidence of complete nasal blockage on either one or both sides on anterior&#xD;
                  rhinoscopy within 30 minutes prior to dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Safety concerns:&#xD;
&#xD;
          1. History of allergic reaction to azelastine hydrochloride or fluticasone propionate or&#xD;
             one of the excipients of the study treatments (e.g. benzalkonium chloride, phenylethyl&#xD;
             alcohol, microcrystalline cellulose) or a component of the container.&#xD;
&#xD;
          2. History of anaphylaxis, cardiovascular, pulmonary, hepatic, renal, gastrointestinal,&#xD;
             haematological, endocrine, metabolic, psychiatric, neurological, or other disease at&#xD;
             screening that may affect subject safety during the study or evaluation of the study&#xD;
             endpoints at the discretion of the Investigator and/or designee.&#xD;
&#xD;
          3. Subjects with a current diagnosis of asthma or subjects with measured FEV1 &lt;75% of the&#xD;
             predicted value using Global Lung Function Initiative set from 2012 for references.&#xD;
&#xD;
          4. Pregnant, breast-feeding or planning a pregnancy during the study and women of&#xD;
             childbearing potential not using adequate contraception. Women of childbearing&#xD;
             potential not abstinent or using a highly effective method of birth control defined as&#xD;
             those which result in a low failure rate (i.e. &lt;1% per year) when used consistently&#xD;
             and correctly such as implants, injectables, combined oral contraceptives, hormonal&#xD;
             IUDs, barrier methods, or tubal ligation started at least 4 weeks prior to screening.&#xD;
&#xD;
             Lack of suitability for the study:&#xD;
&#xD;
          5. Previous and concomitant treatments: use of prohibited therapies (Antihistaminic&#xD;
             agents, all presentations; Theophylline, all presentations; Cromolyn sodium, all&#xD;
             forms; Nedocromil sodium; Salbutamol, all presentations; Leukotriene modifiers, all&#xD;
             presentations; Corticosteroids (inhaled, oral, intravenous); Topical corticosteroids&#xD;
             (ocular, intranasal); Corticosteroids (intramuscular or intra-articular);&#xD;
             Decongestants, all forms; Immunotherapy; Systemic antibiotics; Tricyclic&#xD;
             antidepressants and MAO inhibitors; Any cytochrome P450 3A4 inhibiting or inducing&#xD;
             drug (e.g. ritonavir, cobicistat, ketoconazole, itraconazole, erythromycin,&#xD;
             cimetidine, rifampicin, St. John's wort (Hypericum perforatum) etc.) not allowed&#xD;
             within specific time frames prior to Screening and/or not allowed/allowed only with&#xD;
             restrictions during the study, as specified in the study protocol; use of any&#xD;
             medication considered to have an influence on the outcome of the study during the EEU&#xD;
             session, at the discretion of the Investigator and/or designee.&#xD;
&#xD;
          6. Subjects with (expected) clinically relevant symptoms at the timing of the scheduled&#xD;
             EEU assessments due to concomitant allergies, i.e. history of allergic response to the&#xD;
             causative allergen, at the discretion of the Investigator. Subjects with a positive&#xD;
             SPT for cats and/or dogs are acceptable if the subject avoids cats and/or dogs for the&#xD;
             duration of the study.&#xD;
&#xD;
          7. Concomitant diseases: abnormalities during the screening visit (Visit 1) or Visit 2&#xD;
             that might interfere with study results as determined by the Investigator and/or&#xD;
             designee.&#xD;
&#xD;
          8. Presence of a severely deviated septum, septal perforation, structural nasal defect or&#xD;
             large nasal polyps causing obstruction as determined by the Investigator.&#xD;
&#xD;
          9. Acute conditions: any acute illness within 7 days prior to the screening visit (Visit&#xD;
             1) or Visit 2, including acute conjunctivitis or any other ocular infection, at the&#xD;
             discretion of the Investigator and/or designee.&#xD;
&#xD;
         10. History of increased ocular pressure, glaucoma, cataracts, and/or central serous&#xD;
             chorioretinopathy (CSCR).&#xD;
&#xD;
         11. Presence of or ongoing tuberculosis, untreated local or systemic fungal or bacterial&#xD;
             infections, systemic viral or parasitic infections or ocular herpes simplex.&#xD;
&#xD;
         12. Recent nasal ulcers, mucosal erosion, nasal surgery, or nasal trauma, that might&#xD;
             interfere with study results as determined by the Investigator and/or designee.&#xD;
&#xD;
         13. Exposure to chickenpox or measles within 4 weeks prior to the screening visit or&#xD;
             during the study.&#xD;
&#xD;
         14. Acute or chronic sinusitis or non-allergic rhinitis, at the discretion of the&#xD;
             Investigator and/or designee.&#xD;
&#xD;
         15. Exposure to another investigational product within the last 30 days prior to&#xD;
             screening.&#xD;
&#xD;
         16. History of malignancy within the past five years, except for basal cell skin&#xD;
             carcinomas that have been treated with no recurrence for at least 3 months.&#xD;
&#xD;
         17. Neurological or psychiatric disease or drug or alcohol abuse which would interfere&#xD;
             with the subject's proper completion of the protocol assignment. Subjects with a&#xD;
             positive urine drug screen will be excluded.&#xD;
&#xD;
         18. Subjects undergoing surgical procedures with general anaesthesia within 90 days prior&#xD;
             to screening or who plan to undergo surgery/hospitalization during the study.&#xD;
&#xD;
             Administrative reasons:&#xD;
&#xD;
         19. Vulnerable subjects (such as persons who are institutionalized).&#xD;
&#xD;
         20. Positive alcohol or drug test during screening visit (Visit 1)&#xD;
&#xD;
         21. Public health emergency (e.g. COVID-19): subjects not complying to Public health&#xD;
             guidelines (e.g. self isolation etc.), at the discretion of the Investigator's and/or&#xD;
             designee, or subjects with a positive COVID-test at Visit 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Couroux, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliantha Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rainer Porrmann</last_name>
    <phone>+49 6172 888</phone>
    <phone_ext>2208</phone_ext>
    <email>rainer.porrmann@viatris.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Kolb</last_name>
    <phone>+49 6172 888</phone>
    <phone_ext>2511</phone_ext>
    <email>christine.kolb@viatris.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliantha Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Couroux, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

